Ibex Wealth Advisors Buys 872 Shares of Amgen Inc. (NASDAQ:AMGN)

Ibex Wealth Advisors boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,835 shares of the medical research company's stock after acquiring an additional 872 shares during the period. Amgen accounts for about 1.1% of Ibex Wealth Advisors' investment portfolio, making the stock its 28th largest holding. Ibex Wealth Advisors' holdings in Amgen were worth $8,672,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $25,000. Pinney & Scofield Inc. bought a new stake in Amgen in the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE raised its position in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in Amgen during the 4th quarter valued at about $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen in the fourth quarter worth approximately $34,000. Institutional investors own 76.50% of the company's stock.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is currently owned by insiders.

Amgen Trading Up 1.2%

Shares of NASDAQ:AMGN traded up $3.45 during trading on Tuesday, hitting $293.43. The company had a trading volume of 2,441,018 shares, compared to its average volume of 2,808,700. The stock has a market cap of $157.78 billion, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a fifty day simple moving average of $281.26 and a two-hundred day simple moving average of $285.36. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period in the previous year, the firm earned $3.96 earnings per share. Amgen's quarterly revenue was up 9.4% compared to the same quarter last year. As a group, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have commented on the company. Guggenheim started coverage on Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 target price on the stock. Mizuho raised their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Bank of America upped their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler lowered their price objective on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.